- Home
- SRV vs IVA Comparison
SRV vs IVA Comparison
Compare SRV & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRV
- IVA
- Stock Information
- Founded
- SRV 2007
- IVA 2011
- Country
- SRV United States
- IVA France
- Employees
- SRV N/A
- IVA N/A
- Industry
- SRV Finance Companies
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- SRV Finance
- IVA Health Care
- Exchange
- SRV Nasdaq
- IVA Nasdaq
- Market Cap
- SRV 123.3M
- IVA 117.3M
- IPO Year
- SRV N/A
- IVA 2020
- Fundamental
- Price
- SRV $42.29
- IVA $2.35
- Analyst Decision
- SRV
- IVA Strong Buy
- Analyst Count
- SRV 0
- IVA 4
- Target Price
- SRV N/A
- IVA $13.25
- AVG Volume (30 Days)
- SRV 33.9K
- IVA 9.3K
- Earning Date
- SRV 01-01-0001
- IVA 09-25-2024
- Dividend Yield
- SRV 13.38%
- IVA N/A
- EPS Growth
- SRV N/A
- IVA N/A
- EPS
- SRV N/A
- IVA N/A
- Revenue
- SRV N/A
- IVA $20,652,523.00
- Revenue This Year
- SRV N/A
- IVA N/A
- Revenue Next Year
- SRV N/A
- IVA $361.78
- P/E Ratio
- SRV N/A
- IVA N/A
- Revenue Growth
- SRV N/A
- IVA N/A
- 52 Week Low
- SRV $30.73
- IVA $1.53
- 52 Week High
- SRV $44.30
- IVA $4.75
- Technical
- Relative Strength Index (RSI)
- SRV 40.18
- IVA 36.64
- Support Level
- SRV $44.46
- IVA $2.22
- Resistance Level
- SRV $45.14
- IVA $2.39
- Average True Range (ATR)
- SRV 1.10
- IVA 0.10
- MACD
- SRV -0.45
- IVA -0.03
- Stochastic Oscillator
- SRV 31.62
- IVA 24.76
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.